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Summary The purpose of the ASES study is to determine the clinical characteristics
of Spanish asthmatic patients seen in primary care (PC) and in pneumology (P)
departments, comparing the availability of diagnostic methods, morbidity, the type
of treatment and follow-up between the two health care settings. ASES is a
multicenter, descriptive, cross-sectional study. The physicians were selected by
random sampling. The data were collected by the participating physicians using three
questionnaires. Data were collected on 2349 asthmatic patients (1298 from hospitals
and 1051 from PC). Smokers predominated in the PC setting (P ¼ 0:000). The
spirometry was performed at least once a year in 87.2% of the patients seen in P and
39.8% in PC (P ¼ 0:000). Morbidity was high in both groups (P and PC), more than two
nighttime awakenings per month (25.5% versus 29%) and emergency visits in previous
year (26% versus 21%). A high percent of asthmatic patients was using both inhaled
corticoids and long-acting b2-agonists (49.5% versus 32%). The 30% of PC patients
could not be classified into any step of the treatment. In Spain, the morbidity of
disease is high, despite the large use of drugs. Objective monitoring tests have very
limited use in PC.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
An increase in asthma prevalence not attributable
to improved diagnostic methods has been seen in
many countries all over the world in recent
years.1,2 At the same time, a high morbidity has
been detected which may be attributed, at least in
part, to deficient patient medical care.3,4 Asthma is
a potentially fatal disease,5 but most deaths could
be avoided with preventive measures, particularly
self-treatment protocols.6,7
Various studies indicate that asthmatics are
inadequately treated in many countries.3,8–10 In
order to improve medical care to asthma patients,
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knowledge should be obtained of the situation of
asthma in the setting where improvements are
contemplated, identifying the diagnostic methods
used, the control of the disease, and the char-
acteristics of treatment and of the follow-up
measures applied in routine clinical practice.
Most asthmatic patients are treated by primary
care (PC) physicians, both in Spain and elsewhere.
The rest of patients are seen by specialists in
pneumology (P), and only a small percentage are
managed by other specialists (allergologists, inter-
nists).11,12
Some studies have found differences in the care
of asthmatics by PC physicians or ‘‘specialists’’.13,14
These differences have been attributed to the time
dedicated to the patients and to professional
knowledge. It would therefore be desirable to
know the differences between these two groups
of physicians in Spain, with the aim of improving
coordination between them in the care of asth-
matic patients.
One of the main problems for assessing adequate
professional care is the lack of specific and
universally accepted guidelines. In the case of
asthma, national15 and international16 consensus,
guidelines are available as a reference for all
health care professionals involved in the manage-
ment of asthmatic patients.
The aim of our study is to determine the
characteristics and clinical status of Spanish asth-
matics seen in the PC and P settings, and to
ascertain the existing differences in the availability
of diagnostic methods, the morbidity rate, the type
of treatment and the monitoring between the two
health care settings.
Material and methods
This is a multicenter, descriptive, cross-sectional
study to collect data on the characteristics of
asthmatic patients seen at PC offices and hospital P
outpatient clinics throughout Spain. The ASES study
was coordinated by a Scientific Committee com-
posed of an Asthma Area delegate from the Spanish
Society of Pneumology and Chest Surgery (Sociedad
Espa *nola de Neumolog!ıa y Cirug!ıa Tor!acica, SEPAR)
and another from the Respiratory Group in Primary
Care (Grupo de Respiratorio en Atenci!on Primaria,
GRAP).
In order to avoid seasonal bias, data on asth-
matics were collected during two 4-month periods
from October 1, 1998 to January 31, 1999 and from
March 1, 1999 to June 30, 1999, respectively.
PC physicians were selected by stratified random
sampling in proportion to the regional population.
To this effect, the Spanish territory was divided
into five areas, excluding the non-mainland areas of
the Canary Islands, the Balearic Islands, Ceuta and
Melilla for logistical reasons. Pneumologists were
selected by random block samplingFthe sampling
unit in this case being the Department of Pneumol-
ogy rather than the individual physician. A list was
prepared by Autonomous Communities, selecting
only those Departments of Pneumology belonging
to hospitals ascribed to the public health care
system (Table 1).
All selected physicians were requested by mail to
agree to participation in the study. Those who
failed to give agreement were excluded, as were
those whose occupational characteristics precluded
adequate collaboration during the study (emer-
gency care physicians and/or reinforcements, sub-
stitutions and physicians pending transfer). The
excluded physicians were systematically replaced
by the individual immediately following on the
randomization list.
The required sample size for maximum indeter-
mination of the test parameters (p ¼ q ¼ 0:5), with
a 95% confidence interval (CI) and a precision of 3%,
was 1608 patients per study period, assuming 20%
potential losses.
The 134 PC physicians selected were required to
collect information on 12 asthmatics systematically
selected during the 4 months of each period (the
first three patients attending each month for
consultation concerning any aspect related to
asthma, including prescriptions, etc.). Physicians
who voluntarily withdrew during the study or who
failed to respond or submit any data were not
replaced and were regarded as non-responses.
Fifty-eight Departments of Pneumology were
selected, nine of which were divided into two units
based on the population they covered, thus yielding
a final total of 67 units. Each unit was requested to
collect data from 15 patients systematically se-
lected during the 4 months of each of the two
periods, in a way similar to PC.
Three questionnaires were prepared and sent to
the selected PC and P physicians. One question-
naire was intended to record data concerning the
organization and infrastructure at the different
centres (location, population seen, availability of
diagnostic means), and was completed by each
professional once at the start of each period.
Another questionnaire was designed to calculate
the prevalence of asthma in the population seen
(visits for asthma compared to the total visits
during the study period), and was completed by the
physician at the end of each period. Finally, the
third questionnaire recorded the sociodemo-
graphic, diagnostic, morbidity and treatment data
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of each patient studied, and was completed by the
physician during the interview with each asthmatic.
This last questionnaire also documented the pa-
tient spirometric and/or peak expiratory flow (PEF)
values obtained on the day of the interview.
The three questionnaires were subjected to pilot
evaluation before the start of the study using 10
physicians pertaining to the health care area of
Gij !on (Asturias). Following this pilot period, some
changes were made in the questionnaires in order
to improve comprehensibility.
If no response had been received 2 weeks after
the deadline, the participants were contacted by
telephone in an attempt to obtain the required
information. Four months after the end of the last
study period (i.e., October 31, 1999), data collec-
tion was definitively closed.
A descriptive statistical analysis was made using
means and standard deviations (SD) for the quanti-
tative variables and proportions for the qualitative
variables. For comparing the data from the PC and
P settings, Student’s t-test was used for the
quantitative variables, and a Z-test to compare
proportions for the qualitative variables. The 95%
CI were calculated in all cases. Bilateral statistical
significance was considered for P ¼ 0:05 in all
analyses. SPSS version 9.0 for Windows, Primer
statistics 1.0, and CIA (Confidence Interval Analysis)
1.0 were used for statistical processing.
Results
Of the selected samples, a total of 106 PC
physicians started participation in the ASES study;
34 of these withdrew before the end of the
studyFthe response rate therefore being 58%
(n ¼ 72). As regards the P units, 79% responded
(n ¼ 53). The potential differences between the
physicians who completed both study periods and
those who withdrew before completion were
analyzed, and no significant differences were found
in terms of age, sex, specialty, population size or
geographic area.
Data from 2349 asthmatic patients were col-
lected (1051 in PC and 1298 in the P setting). The
mean age was 46721 years in PC and 46719 years
in P. There were significantly more smokers in PC
than in P (P ¼ 0:000). The rest of the differences
are shown in Table 2.
The proportion of consultations for asthma with
respect to total consultations was 32% in P and 4%
in PC.
Spirometry was performed at the time of
consultation in 80% of the hospitals, while only
50% of the PC physicians had access to this
ARTICLE IN PRESS
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diagnostic method. Among the latter, 25% could
request spirometry directly from their specialized
reference center, while the rest had no choice but
to refer the patients elsewhere.
On the other hand, 87% (CI: 85.4–89.0) of the
patients seen in P were subjected to spirometry at
least once a year, while spirometry was not
performed at any time in only 3% (CI: 2.2–4.2). In
PC, spirometry was carried out at least once a year
in only 40% of the patients (CI: 36.8–42.7), and
never in 23% (CI: 20.6–25.7). These differences
were statistically significant (P ¼ 0:000).
On the day of the interview, spirometry data
were recorded in 1168 patients seen in P (90%; CI:
88.4–91.6), and PEF data in 898 (69%; CI: 66.7–
71.7). By contrast, in the PC setting, spirometric
data were recorded in 341 patients (32%; CI: 29.6–
35.3), and PEF data in 159 (15%; CI: 13.0–17.3)
(P ¼ 0:000).
The spirometric values recorded were similar in
both groups of patients. Thus, an FEV1 of over 80%
of the theoretical value was recorded in 58% (CI:
55–60.7) of the P group and in 52% (CI: 46.3–56.9)
of the PC group. In turn, an FEV1 of under 60% of
the theoretical value was recorded in 18%
(CI: 16.1–20.5) of the patients seen in P and in
21% (CI: 16.8–25.4) of those seen in PC. Finally, 24%
(CI: 21.4–26.2) of the P group and 27% (CI: 22.5–32)
of the PC group yielded FEV1 values between 60%
and 80% of the theoretical value.
The morbidity of asthmatic patients was high in
both groups. It should be stressed that the P group
showed a greater number of visits to the emergency
department, hospital admissions and admissions to
intensive care units than the PC group. By contrast,
the latter showed more work and school absentee-
ism and made greater daily use of short-acting b2-
agonists (Table 3).
Differences between the two groups were re-
corded in the type of medication used to treat
asthma (Table 4). Thus, 90% (CI: 88–91.3) of the
patients seen in P used inhaled corticoids versus
62.5% (CI: 59.6–65.4) of those seen in PC
(P ¼ 0:000); budesonide was the most widely
used drug in both groups. The P group also used
significantly more long-acting b2-agonists (56%,
CI: 53.8–59.2) than the PC group (44%; CI:
41.2–47.2), as well as more short-acting b2-
agonists (92%; CI: 90–93.1 versus 81.6%, CI:
79.3–84) (P ¼ 0:000 for both). However, other
drugs were more widely used in PC (antihista=
mines, nedocromil, ipratropium bromide and im-
munotherapy) (Po0:05). When grouped by associa-
tions and recommended doses, the PC group was
seen to use fewer high-dose inhaled corticoids
and in combination with long-acting b2-agonists,
and more non-classifiable treatments were admi-
nistered (mucolytic agents, antitussive drugs)
(Table 5).
Some particularities were seen. Thus, 0.8% (CI:
0.3–1.4) of the patients seen in P used inhaled
corticoids as needed, but this figure increased to 3%
(CI: 1.9–4) in the PC group. By contrast, 26% (CI:
23–28.3) of the asthmatics seen in PC have been
ARTICLE IN PRESS
Table 2 Sociodemographic characteristics of the asthmatic patients in both groups.
Hospital Primary care P
No. % (CI 95%) No. % (CI 95%)
Age 1298 46 (44,6–47,1) 1051 46(44,6–46-,8) NS
Sex
Males 477 37 (34.1–39.4) 453 43 (40.1–46.1) NS
Females 821 63 (60.6–65.9) 598 57 (53.9–59.9) NS
Smoking
Non-smoker 946 73 (70.5–75.3) 691 66 (62.9–68.6) 0.0001
Exsmoker 251 19 (17.2–21.5) 181 17 (14.9–19.5) NS
Smoker 101 8 (6.3–9.3) 179 17 (14.8–19.3) 0.0000
Occupational status
Unemployed 57 4 (3.3–5.6) 42 4 (2.9–5.3) NS
Housewife 417 32 (29.6–34.7) 290 28 (24.9–30.3) 0.01
Student 207 16 (14–17.9) 205 19.5 (17.1–21.9) 0.02
Active 422 32.5 (30–35.1) 290 28 (24.9–30.3) 0.01
Retired 179 14 (11.9–15.7) 204 19 (17–21.8) 0.0002
Early retirement 16 1 (0.7–2) 20 2 (1.1–2.9) NS
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prescribed a short-acting b2-agonist, as compared
to only 2% (CI: 1.2–2.8) in the P group. Long-acting
b2-agonists were used without inhaled corticoids in
1% (CI: 0.5–1.8) of the patients seen in P and in 11%
(CI: 8.7–12.4) of those seen in PC. In turn, 2% (CI:
1–2.6) of the PC group used long-acting b2-agonists
as needed, this figure dropping to 0.5% (CI: 0.1–1.1)
in the P setting. It should also be mentioned that 3%
(CI: 2.3–4.6) of the PC group (n ¼ 35) received
theophylline as the only treatment, while this only
occurred in two patients from the P group (0.1%; CI:
0.01–0.5).
As regards other treatment measures, 75.5% (CI:
73.2–77.8) of the patients seen in P were given
information on environmental measures to prevent
asthma attacks, while this proportion increased to
81% (CI: 78.3–83.1) in PC. Likewise, written self-
treatment plans were distributed among the
patients in both health care settings: 66% (CI:
63.2–68.4) in the P group and 61.5% (CI: 58.5–64.4)
in PC. By contrast, daily PEF measurements in the
home were made by 25% (CI: 23–27.7) of the P
patients versus only 5% (CI: 3.6–6.3) of those seen
in PC (P ¼ 0:000).
Discussion
This study addresses some aspects of asthma
management in Spain from the perspective of the
physician, and shows an inadequate use of objec-
tive measures for patient monitoring, a high
morbidity and a high proportion of inadequate
treatments.
One limitation of the study is the high percentage
(42%) of PC physicians who failed to respond,
though this fact probably has little influence upon
the results obtained, since no differences were
seen between the physicians who responded and
those who did not.
Other limitations are inherent to the cross-
sectional study design, using the medical diagnosis
of asthma and therefore not including patients not
diagnosed or those who do not visit the doctor.
Thus, the results refer only to the clinical care of
patients diagnosed of asthma who regularly visit
their physician (consulting population). It has not
been possible to take into account the severity of
asthmatic patients as it was not possible to classify
them according to clinical and functional criteria
given that most of them were on treatment.
Therefore, the comparison between both popula-
tions (PC and P) has this constraint; although it is
important, we considered it to be of little
relevance to the objective of the study which was
to describe the situation in each one the health
care settings.
One of the most striking findings of the study is
the scant use made in the PC setting of objective
measures to monitor asthmatic patients. Thus,
spirometry is never performed to one-quarter of
asthmatic patients, while in 60% of the cases
spirometry is never done or is performed less than
once a year. These observations contrast with the
recommendations of the guidelines for asthma
treatment,15,16 where emphasis is placed on the
significance of assessing pulmonary function in the
monitoring of asthmatic patients. Such functional
assessment is advised at least once a year, and
ideally whenever the patient is seen. The PEF
meter can replace spirometry when the latter is not
available, but this simple and inexpensive device is
used even less than spirometry.
One of the aims of treatment is to achieve a
pulmonary function that is normal or as normal as
possible. However, this objective is difficult to
achieve if pulmonary function is not even tested. It
ARTICLE IN PRESS
Table 3 Morbidity data in each group of asthmatic patients.
Hospital Primary care P
No. % (CI 95%) No. % (CI 95%)
Symptoms more than once a week 411 32 (29.1–34.2) 253 24 (21.5–26.7) 0.000
More than two nighttime awakenings a month 331 25.5 (23.1–27.9) 304 29 (26.2–31.7) 0.072
Work or school absenteeism 207 16 (14–17.9) 229 22 (19.3–24.3) 0.000
Emergency visits in previous year 339 26 (23.7–28.5) 222 21 (18.7–23.6) 0.005
Hospital admission in previous year 172 13 (11.4–15.1) 100 9.5 (7.8–11.5) 0.005
Ever admitted to intensive care unit 84 6.5 (5.1–7.9) 31 3 (2–4.1) 0.000
Daily use of short-acting b2-agonists 155 12 (10.2–13.7) 190 18 (15.8–20.4) 0.000
Oral corticoid cycles in the past 6 months 273 21 (18.8–23.2) 227 22 (19.1–24.1) 0.762
876 A. Lo´pez-Vin˜a et al.
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could be thought that the reason for this is a lack of
spirometers and PEF meters, but the reason is more
likely to be that physicians are unaware of their
importance or simply consider them of little value,
since access at least to a PEF meter is usually easy
and cheap. In the P units the situation is different,
since only 3.2% of the patients were never
subjected to spirometry, and over 80% were
evaluated by this technique at least once a year.
This lack of use of pulmonary function test agrees
with the Spanish data of the AIRE study,17 where
65% of all patients reported never having been
subjected to spirometry, and an additional 26% said
that no such study had been made on them in the
previous year. These figures are higher than the
European averages. Therefore, from the patient
perspective (the AIRE data were collected from the
patients), the problem is even worse.
It is most probable that the patients seen in P are
more severe than the patients seen in PC as the
indirect data (greater number of visits to the
emergency room and of hospitalizations as well as
a greater number of patients receiving treatment
with high doses of corticosteroids and these in
combination with long-lasting b2-agonists) are
indicative of this. In any case as in other studies,
patient morbidity was high17,18 in both the PC and P
setting. More than 25% of the asthmatics woke up
at night two or more times a month, while 19%
missed work or school, 24% visited the emergency
department in the previous year, and 12% were
admitted to hospital in the previous year because
of asthma.
One of the reasons for poor asthma control is
prescription of inadequate treatment,19,20 though
this does not seem to have been the main cause in
our study, at least in the population seen in the P
units (90% were receiving inhaled corticoids, and
94% could be classified on some severity stage).
Inadequate treatment could have been the cause of
high morbidity in only 30% of patients seen in PC
who could not be classified in any severity stage,
but in the remaining 70% inadequate therapy does
not seem to be the main cause either.
Inadequate monitoring of therapeutic objectives
and poor treatment compliance could be the
reasons for this discrepancy between morbidity
and treatment. In the AIRE study,17 only 15% of
the patients were receiving inhaled corticoids. The
difference between what the physicians claim to
be prescribing and what the patients claim to be
receiving is too great, and suggests that poor
patient compliance is one of the causes of high
morbidity.
An interesting finding is the existence among the
asthmatics seen in PC of more than twice as many
smokers as in P. These data are similar to those
found in two studies conducted in Australia and the
United States,13,14 but which the authors overlook.
One reason could be that hospitals deal with the
more serious asthma cases, who do not smoke
because of the severity of their disease (the
percentage of former smokers is similar), but
another possible explanation is that PC physicians
and the smoking asthmatics themselves attribute
the symptoms to smoking and consequently request
less hospital intervention. In the European study,21
smoker status was strongly associated with non-
acknowledgement of the disease, thus suggesting
that the symptoms are attributed to smoking, as a
result of which the patient does not report to the
doctor. Even after diagnosis, the patients at least
partially continue to blame the symptoms on
smoking. One study has shown that asthmatic
children with smoking parents are not adequately
treated22 because the parents tend to take them
less to see the doctor. Taken together, all these
data suggest that tobacco smoking appears to lead
to deficient management of asthmatic patients, the
responsibility for this situation possibly being
distributed among the parents, patients and physi-
cians. Medical professionals should take this aspect
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Table 5 Type of treatment used in each group of asthmatic patients.
Hospital Primary care P
No % (CI 95%) No % (CI 95%)
No treatment 4 0.3 (0.07–0.7) 17 2 (0.9–2.5) 0.002
Only short-acting b2-agonists as needed 87 7 (5.4–8.2) 113 11 (8.8–12.6) 0.000
Low-dose inhaled corticosteroidsa 174 13(11.6–15.3) 133 13 (10.6–14.7) 0.661
High-dose inhaled corticosteroidsb 227 17 (15.4–19.6) 92 9 (7.1–10.6) 0.000
Inhaled corticosteroids+long-acting b2-agonists 643 49.5 (46.8–52.3) 335 32 (29.1–34.7) 0.000
Oral corticosteroids 88 7 (5.4–8.2) 42 4 (2.9–5.3) 0.006
Non-classifiable 75 6 (4.5–7.1) 319 30 (27.6–33.1) 0.000
aLow-dose inhaled corticosteroidsp500mg/day of beclomethasone or budesonidep250mg/day of fluticasone.
bHigh-dose inhaled corticosteroidsX500mg/day of beclomethasone or budesonideX250mg/day of fluticasone.
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into account, retaining asthma control as the
primary treatment aim even if the patient smokes.
PEF monitoring is recommended for the follow-
up of asthmatic patients.15,16 In this study, only
one-fifth of the asthmatics seen in PC used the PEF
meter at home, as compared to 25% of those seen in
the P setting. Both proportions are very low.
Surprisingly, the physicians claim that most pa-
tients have received self-treatment instructions.
This data agree with those of the AIRE study,
according to which Spain is the participating
European country with the largest percentage of
patients with self-treatment plans. We have no
explanation for this finding, but an erroneous
understanding of what is meant by a self-treatment
plan may be responsible, together with the
misconception that b2-agonist rescue medication
constitutes such a plan. The low proportion of
patients with PEF monitoring suggests that in fact
few self-treatment plans contemplate increased
inhaled corticoids or the use of oral corticoids
under certain circumstances. Such plans are the
ones actually having an impact upon asthma
morbidity and mortality.6
The differences between PC and P in the way the
pulmonary function test was used may reflect
differences the working conditions (less time
available per patient, less spirometers) and the
fact that there is less specific training in PC. To
improve this situation a better cooperation would
be necessary between the two health care settings
as well as the development of ongoing training
programmes in PC.
To summarize, objective methods used are very
little in PC for the monitoring of asthmatic
patients. Morbidity associated with the disease is
very high both in the PC and P setting, possibly due
to inadequate monitoring of therapeutic objectives
by health professionals and to poor patient com-
pliance with treatment, due to a lack of educa-
tional strategies for improving patient adhesion.
The improved care of asthmatic patients in Spain
therefore requires an increased use of objective
monitoring tests in PC (i.e., spirometers and PEF
meters). Moreover, in both PC and P, emphasis
should be placed on the need to monitor the
established therapeutic objectives and the conve-
nience of implementing patient education pro-
grams to afford increased patient autonomy and
better treatment compliance.
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Valdes, C.S. Nicol !as Perez Jimenez (Cabeza del
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Benavides de Orbigo; Andres Castillejo Alvarez,
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